🇺🇸 Livdelzi in United States

FDA authorised Livdelzi on 14 August 2024

Marketing authorisations

FDA — authorised 14 August 2024

Application: NDA217899
Marketing authorisation holder: GILEAD SCIENCES INC
Local brand name: LIVDELZI
Indication: CAPSULE — ORAL
Status: approved

GILEAD SCIENCES INC's Livdelzi has been granted marketing authorisation by the FDA. The approval was issued on August 14, 2024, under the application number NDA217899. The drug was approved as a new molecular entity, but the specific indication for which it was approved is not reported.

Read official source →

FDA

Marketing authorisation holder: GILEAD SCIENCES INC
Status: approved

Livdelzi in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Metabolic approved in United States

Frequently asked questions

Is Livdelzi approved in United States?

Yes. FDA authorised it on 14 August 2024; FDA has authorised it.

Who is the marketing authorisation holder for Livdelzi in United States?

GILEAD SCIENCES INC holds the US marketing authorisation.